Nimbles Biotech Pvt. Ltd.

What Nimbles Biotech Pvt. Ltd. does

Nimbles Biotech Pvt. Ltd. is an Indian pharmaceutical company founded in 2008 in Ambala Cantt, Haryana, operating a PCD Pharma Franchise model, third-party contract manufacturing, and direct product sales. The company manufactures and distributes a portfolio of over 100 pharmaceutical products spanning tablets, hard gel capsules, soft gel capsules, injectables, syrups, pediatric suspensions, ointments, herbal products, protein powders, sachets, and nutraceuticals, with all production conducted at WHO-GMP, ISO 9001:2008, and DCGI-compliant facilities. Its core technology is conventional pharmaceutical formulation and manufacturing rather than proprietary platforms or novel drug development, with products primarily composed of generic and off-patent molecules across antibiotics, antifungals, antivirals, anti-inflammatories, corticosteroids, gastro-intestinal, cardiovascular, and neurology therapeutic categories.

The business generates revenue through three channels: PCD Pharma Franchise rights granted to entrepreneur-partners who purchase products at wholesale PTR/PTS rates and sell at MRP within territory-based monopoly rights; third-party manufacturing services where external pharma firms contract Nimbles to produce formulations under their specifications; and direct product sales to retailers and stockists. Pricing is publicly disclosed on the website with transparent MRP, PTR, and PTS values, supported by an online calculator tool. The customer base consists of individual franchise entrepreneurs and mid-market distribution partners across 20+ Indian states, with no large enterprise anchors disclosed.

The company operates as a multi-brand house with five divisions: Philanto Wellness (third-party manufacturing), Philanto Healthcare, Alzara Pharmaceuticals (neurology and mental health), Adcid Pharma, and Modena (cosmetic and dermatological products). Nimbles Biotech is founder-led by Managing Director Dinesh Raghav, employs 51-100 staff, and describes itself as a zero-debt, bootstrapped entity with no disclosed venture capital or private equity investment. Eight new SKUs were launched between March and July 2025, signaling active product pipeline expansion.

Name

Nimbles Biotech Pvt. Ltd.

Legal name

Nimbles Biotech Pvt. Ltd.

Website

https://nimblesbiotech.in

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Nimbles Biotech is an Indian pharmaceutical company founded in 2008 that manufactures and distributes 100+ generic formulations through PCD franchise partners, third-party manufacturing, and direct sales across 20+ Indian states under five divisions.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Pharmaceutical manufacturing
• PCD pharma franchise
• Third party manufacturing
• Generic formulations
• Pharmaceutical distribution

Headquarters

HQ city

Ambala Cantt

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. PCD Pharma Franchise: Granting franchise rights to entrepreneurs and business owners to market and distribute pharmaceutical products under the Nimbles Biotech brand name in specific geographic territories. Revenue generated through product sales to franchise partners at wholesale/PT rates.
2. Third Party Pharma Manufacturing: Contract manufacturing services where other pharmaceutical companies hire Nimbles Biotech to produce their pharmaceutical products. The contracting company provides formula, specifications, and sometimes packing materials while Nimbles handles actual manufacturing.
3. Direct Product Sales: Direct sales of pharmaceutical products (tablets, capsules, syrups, injectables, etc.) to retailers, stockists, and healthcare providers at MRP and PTR/PTS rates.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Nimbles Biotech is an Indian pharmaceutical manufacturer that produces generic and branded formulations (tablets, capsules, syrups, injectables, ointments, and herbal products) and sells them via a PCD Pharma Franchise model and Third Party / Contract Manufacturing services. The company operates WHO-GMP certified facilities under an ISO 9001:2008 quality system and supplies franchise partners and brand owners with a portfolio of 100+ products across wellness and therapeutic divisions.

Product overview

Nimbles Biotech Pvt. Ltd. is a pharmaceutical company offering a diversified portfolio of over 100 pharmaceutical products across multiple categories including Tablets, Hard Gel Capsules, Soft Gel Capsules, Cardiac & Diabetic, Critical Care Range, Dental, Drops, Herbal Products, Injectables, Pediatric, Syrups, Protein Powder & Sachets, Nano Shots, Ointments, and Lotions/Powders/Soaps/Shampoos. The company operates through multiple divisions including Philanto Wellness, Philanto Healthcare, Alzara Pharmaceuticals (neurology/mental health), ADCID, and Modena (cosmetic/dermatological). Nimbles Biotech provides PCD Pharma Franchise opportunities and Third Party Pharma Manufacturing services, with all products manufactured in WHO-GMP certified facilities. The company also offers a PTR & PTS Calculator tool for pharmaceutical business calculations.

Differentiator

Problem solved

Functional benefit

Brands

• Philanto Wellness: Third party pharmaceutical manufacturing company specializing in WHO-GMP certified manufacturing solutions
• Philanto Healthcare
• Alzara Pharmaceuticals
• Adcid Pharma
• Modena

Products and services

• PCD Pharma Franchise Propaganda-cum-distribution franchise model offering pharmaceutical entrepreneurs monopoly territorial rights, promotional inputs, and supply of generic and branded formulations across multiple therapeutic segments.
• Third Party / Contract Manufacturing Contract manufacturing of pharmaceutical formulations (tablets, capsules, syrups, injectables, ointments, herbal products) at WHO-GMP certified, ISO 9001:2008 compliant facilities for client brands and marketing companies.
• Pharmaceutical Formulations Portfolio Range of 100+ generic and branded pharmaceutical formulations including tablets, capsules, syrups, injectables, ointments, and herbal products across divisions (Philanto Wellness, Philanto Healthcare, Alzara Pharmaceuticals, Adcid Pharma, Modena).

Named customers4 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Philanto WellnesscoreOEM/ Whitelabel/ Licensing PartnerRelated entity operating as Nimbles Biotech's own manufacturing unit. Philanto Wellness has established itself as a leading pharmaceutical company in India specializing in third party manufacturing. The entity operates WHO-GMP certified manufacturing facilities.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Cipla: Among India's largest pharma manufacturers, also operating generic formulation, contract manufacturing and broad domestic distribution — overlapping business model but at far larger scale and brand reach.
• Alkem Laboratories: Major Indian pharma manufacturer with a broad generic-therapeutic portfolio and India-wide distribution; comparable at the category level but substantially larger scale.
• Mankind Pharma: Top-tier Indian pharma company that, like Nimbles Biotech, also operates a PCD franchise and third-party distribution model across India with a broad generic-portfolio approach.
• Zydus Lifesciences: Diversified Indian pharma company with generic formulations, biosimilars and contract manufacturing — shares Nimbles' generic-portfolio orientation but operates at far larger scale.
• Sun Pharmaceutical Industries: India's largest pharma company with a deep generic-portfolio and contract manufacturing capabilities; serves as an upper-bound incumbent comparable whose breadth dwarfs Nimbles' scope.
• Lupin Limited: Large Indian generic-pharma manufacturer with portfolio and contract manufacturing comparable in therapeutic breadth, though at materially larger scale than Nimbles.

Direct peers

• Ajanta Pharma: Mid-sized Indian generic-pharma manufacturer with branded generics across therapeutic areas (cardiac, dermatology, ophthalmology) — closely comparable in product breadth and Indian-market distribution orientation.
• Vivimed Labs: Indian specialty-pharma and personal-care company with multiple divisions operating across formulations, contract manufacturing and distribution — analogous multi-division, multi-format structure to Nimbles.
• Indoco Remedies: Indian generic-pharma manufacturer with comparable portfolio of formulations across therapy areas, distributing domestically and to semi-regulated export markets — mirroring Nimbles' tablet/capsule/syrup manufacturing orientation.
• IPCA Laboratories: Indian pharma company focused on generic formulations and APIs with strong domestic distribution and contract manufacturing — comparable in manufacturing-plus-distribution model serving the Indian market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/nimblesbiotechpvtltd

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nimbles Biotech Pvt. Ltd.